Jeonjinbio KRX:110020KOSDAQ
전진바이오팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Jeonjinbio reported revenue of ₩2.9bn, down 19.4% year on year, and an operating loss of ₩261m. Jeonjinbio (전진바이오팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Swung to loss Screener
Jeonjinbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.9bn | -19.4% | −₩261m margin −8.9% | −₩219m |
| Q1 2026 | ₩2.9bn | +33.7% | −₩199m margin −6.9% | −₩171m |
| Q4 2025 derived | ₩3.4bn | -21.8% | −₩278m margin −8.1% | −₩259m |
| Q3 2025 | ₩4.5bn | -15.2% | ₩326m margin 7.3% | ₩341m |
| Q2 2025 | ₩3.6bn | -30.1% | ₩86m margin 2.4% | ₩105m |
| Q1 2025 | ₩2.2bn | -51.1% | −₩476m margin −22.1% | −₩383m |
| Q4 2024 derived | ₩4.4bn | -13.5% | ₩360m margin 8.2% | ₩665m |
| Q3 2024 | ₩5.3bn | +18.4% | ₩502m margin 9.6% | ₩569m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Jeonjinbio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.